Skip to main content

Table 3 Univariate analysis of factors regardingoverall survival (OS) and recurrence-free survival (RFS)

From: Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer

Variable Categorisation Tumour-related death (OS) Tumour recurrence (RFS)
   n events pc n events pc
Clinicopathological data:
Tumour stagea       
  pT1 46 7 <0.0001 44 8 <0.0001
  pT2 74 27   71 32  
  pT3 12 3   11 4  
  pT4 24 16   21 13  
Lymph node statusa       
  pN0 68 9 <0.0001 66 13 <0.0001
  pN1-3 83 40   79 42  
Histological grade       
  G1 16 4 0.005 15 5 <0.0001
  G2 67 16   62 15  
  G3 72 33   70 37  
Multifocality       
  unifocal tumour 130 43 0.545 123 47 0.689
  multifocal tumour 26 10   24 10  
Histological type       
  ductal 130 44 0.787 126 52 0.432
  lobular 11 5   9 2  
  other 13 4   11 3  
Immunohistochemistry (IHC):
Oestrogen receptor status       
  negative (IRS 0–2) 41 17 0.094 41 21 0.034
  positive (IRS 3–12) 89 26   84 26  
Progesterone receptor status       
  negative (IRS 0–2) 95 43 <0.0001 88 43 0.001
  positive (IRS 3–12) 41 5   41 6  
HER2 IHC       
  weak (0–2+) 109 32 0.006 101 37 0.128
  strong (3+) 25 14   25 12  
RAI-3b       
  low (IRS 0–4) 78 25 0.816 76 29 0.897
  abundant (IRS 5–12) 78 28   71 28  
  1. aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
  2. bRAI-3 immunoreactivity: low = IRS 0–4, abundant = IRS 5–12
  3. cLog-rank test (two-sided), bold face representing significant data (P < 0.05)